{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(3)"],"submitter":["Abecassis A"],"pubmed_abstract":["Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at different stages of the disease and investigated their phenotype and capacity to generate functional CAR-T directed against CS1 or B Cell Maturation antigen. We found a decrease in naive T cells and elevated frequencies of exhaustion markers in T cells from treated MM patients. Interestingly, individuals treated with daratumumab display elevated ratios of central memory T cells. CAR-T derived from patients at relapse show reduced in vitro expansion and cytotoxic capacities in response to MM cells compared to those produced at diagnosis. Of n"],"journal":["EJHaem"],"pagination":["970-974"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9421998"],"repository":["biostudies-literature"],"pubmed_title":["CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment."],"pmcid":["PMC9421998"],"pubmed_authors":["Villesuzanne C","Nelson E","Royer B","Talbot A","Garrick D","Fermand JP","Burbridge M","Abecassis A","Harel S","Roders N","Goodhardt M","Choisy C","Bories JC","Fayon M","Arnulf B"],"additional_accession":[]},"is_claimable":false,"name":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.","description":"Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at different stages of the disease and investigated their phenotype and capacity to generate functional CAR-T directed against CS1 or B Cell Maturation antigen. We found a decrease in naive T cells and elevated frequencies of exhaustion markers in T cells from treated MM patients. Interestingly, individuals treated with daratumumab display elevated ratios of central memory T cells. CAR-T derived from patients at relapse show reduced in vitro expansion and cytotoxic capacities in response to MM cells compared to those produced at diagnosis. Of n","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T21:34:43.389Z","creation":"2025-04-04T21:34:43.389Z"},"accession":"S-EPMC9421998","cross_references":{"pubmed":["36051036"],"doi":["10.1002/jha2.479"]}}